INTRODUCTION
HIV-1 causes AIDS, a condition in humans in which the immune system begins to fail, often leading to life-threatening opportunistic infections. One prevalent threat is cryptococcal meningitis, a common manifestation of systemic fungal infection in HIV-infected patients [1, 2] . Approximately 10 % of HIV-1-infected patients in the U.S.A., Western Europe and Australia, as well as 30 % in sub-Saharan Africa, will develop cryptococcal meningitis as an AIDS-defining illness [3] . In approximately 40 % of patients, cryptococcal meningitis may be the initial manifestation of HIV-1 infection [2] . The mortality rate of cryptococcal meningitis in AIDS patients is high. During initial therapy, 10-25 % of these patients die, and 30-60 % succumb within 12 months [3] . Although much work has been done to investigate the unique phenomenon derived from Cryptococcus neoformans in AIDS patients, the exact sequence of disease progression and the relationship between HIV-1 and C. neoformans is not yet understood.
The entry of HIV-1 into target cells, a crucial step of HIV-1 viral pathogenesis, is initiated by the binding of HIV-1 envelope glycoproteins (Env) subunit gp120 to the cellular receptor CD4 and a co-receptor, CXCR4 or CCR5, triggering a series of conformational changes in the Env transmembrane subunit gp41, including the formation of the PFI (prehairpin fusion intermediate) and, then, the hairpin core conformation [4, 5] . In the PFI state, the FP (fusion peptide) inserts into the target cell membrane, whereas the NHR (N-terminal heptad repeat) and CHR (C-terminal heptad repeat) linked by a loop remain exposed [6] (Figure 1 ). The gp41 PFI is an attractive target for anti-HIV therapeutics and vaccines [7] [8] [9] . In the hairpin core state, the CHR and NHR associate to form a core conformation termed 'trimer-of-hairpins' or 'six-helix bundle' [10] [11] [12] , which bring the viral envelope and target cell membrane into close promixity for fusion [13] . Peptides derived from the NHR and CHR regions, named N-and C-peptides, such as SJ-2176 [14] , T20 [15] , and N36 and C34 [16] , can block the hairpin core formation and inhibit HIV fusion/entry. T20 (brand name, Fuzeon; generic name, Enfuvirtide) has been approved by the U.S. FDA (Food and Drug Administration) as the first member of a new class of anti-HIV drugs, HIV-fusion inhibitors [17] .
The HIV-1 gp41 core is not only essential for early co-receptor binding, but is also important for the late process of membrane fusion, such as interacting with the target cell membranes, slowing down membrane disruption effects induced by early exposed gp41, affecting membrane morphology and stabilizing the fusion pore against collapse [18] [19] [20] [21] [22] [23] . It has been shown that the gp41 core domain can interact with epsin [24] , which Abbreviations used: BBB, blood-brain barrier; CHR, C-terminal heptad repeat; CMFDA, 5-chloromethylfluorescein diacetate; CMTPX, 4-(chloromethyl) 6-[4(5)-amino-2-carboxyphenyl]-1,2,2,4,8,10,10,11-octamethyl-1,2,10,11-tetrahydro-dipyrido[3,2-b:2 ,3 -i] xanthylium; CNS, central nervous system; DAPI, 4 ,6-diamidino-2-phenylindole; DMEM, Dulbecco's modified Eagle's medium; ECL, enhanced chemiluminescence; FBS, fetal bovine serum; FP, fusion peptide; HBMEC, human brain microvascular endothelial cell; HRP, horseradish peroxidase; ICAM-1, intercellular adhesion molecule 1; IEM, immunoelectron microscopy; m.o.i., multiplicity of infection; NHR, N-terminal heptad repeat; Ni-NTA, Ni 2 + -nitrilotriacetate; PFI, prehairpin fusion intermediate; PKCα, protein kinase Cα; SEM, scanning electron microscopy; TEM, transmission electron microscopy; WT, wild-type; YPD, 1 % (w/v) yeast extract/2 % (w/v) peptone/2 % (w/v) dextrose. 1 To whom correspondence should be addressed (email ajong@chla.usc.edu). is an essential accessory factor of endocytosis and docks to the plasma membrane by interacting with the lipid, and the gp41 core is also able to bind with the scaffolding domain of caveolin-1, which may be involved in the process of fusion between the HIV-1 envelope and the target cell membrane, or endocytosis of HIV-1 particles [25] . This gp41 ectodomain (amino acids 539-684) could enhance MHC class I and ICAM-1 (intercellular adhesion molecule 1) expression on the T-cells and monocytes [26] , and recently a gp41 core-binding molecule, P20, that has a sequence partly homologous with the human protein TNNI3K (TNNI3-interacting kinase), is effective in blocking HIV-1 Env-mediated cell fusion and syncytium formation [27] . The gp41 N-peptide N36 (amino acids 546-581), the major component of the gp41 core, is able to activate human phagocytes through FPRL1 (Nformyl peptide receptor-like 1) [28] .
Encephalopathy represents a common and serious manifestation of HIV-1 infection (for reviews see [29, 30] ). Note that HIV-1 enters the CNS (central nervous system) shortly after the primary infection [31, 32] , while the BBB (blood-brain barrier) is still strong. Therefore a direct interaction between HIV-1 virions and HBMECs (human brain microvascular endothelial cells), which constitute the BBB, is plausible. It is generally accepted that HIV-1 infection of HBMECs facilitates the viral entry to the CNS, either by invasion of HBMECs or via entry of HIV-infected leucocytes (the Trojan horse mechanism). Previous studies have shown that the entry of HIV-1 virions into HBMECs is a lipid-raftdependent process [33] . The virions were taken into cytoplasmic vesicles through surface invaginations (macropinocytosis). The paracellular route is insignificant. Interestingly, upon cellular entry, HIV-1 virions were entangled by host microvilli structures, as shown by the TEM (transmission electron microscopy) images showing exuberant membrane extrusion trapping virions on the cell surface and in a large surface crater [33] . The mechanism behind this observation is currently unknown. The induction of membrane ruffling can be observed by both pathogenic yeast C. neoformans [34] and HIV-1 virions when they invade HBMECs [33] . We have previously reported that the HIV-1 gp41 ectodomain fragments gp41-I33 (amino acids 579-611) and gp41-I90 (amino acids 550-639), both containing the loop region, can enhance C. neoformans binding to HBMECs, suggesting a potential role for the HIV-1 gp41 in assisting fungi to invade human brain tissues and the CNS [35] . In the present study, we expressed the gp41-I90 and its mutants in Escherichia coli, and used them to explore the underlying mechanism. Our results have shown that, like C. neoformans, gp41-I90 could up-regulate ICAM-1 molecules on the surface of HBMECs. The recombinant gp41-I90 protein was also able to induce marked morphological changes and lipid raft activities in HBMECs. These findings suggest that the HIV-1 gp41 ectodomain is able to activate the membrane components and induce the cytoskeletal rearrangement of HBMECs to facilitate pathogenic invasions. The results of the present study demonstrate a novel function of the HIV-1 gp41 ectodomain on HBMECs, which may play a role as a neurotrophic factor for cryptococcal CNS invasion.
MATERIALS AND METHODS

Reagents and materials
A 270 bp DNA fragment from gp41 was amplified by two primers (gp7451, 5 -GGGGATCCGCAGCAGCAGAACAATTTGCTG-CGTGCT-3 and gp7720, 5 -TATAAGCTTGGTGTAATTGTTA-ATTTCACGGTCCCA-3 ). The resulting PCR DNA fragment was subcloned into the bacterial expression vector pET28b at the BamHI and HindIII sites. The DNA fragment encodes gp41 from amino acids 550 to 639 with T7 and His 6 tags. The mutant template has been described previously [49] . The protein was expressed and refolded in FPLC. The protein was purified on a Ni-NTA (Ni 
Yeast strains
The C. neoformans strain B4500FO2 has been described previously [36] [37] [38] . Yeast cells were grown aerobically at 30
• C in The HBMECs were obtained from Dr Kwang-sik Kim (Johns Hopkins University School of Medicine). The isolation has been described previously [34, [39] [40] [41] [42] . Briefly, brain specimens were cut into small pieces and homogenized in DMEM-S [DMEM (Dulbecco's modified Eagle's medium) containing 2 % FBS] using a Dounce homogenizer with a loose fitting. The homogenate was centrifuged in 15 % dextran in DMEM-S for 10 min at 10 000 g. The pellet containing crude microvessels was further digested in a solution containing 1 mg/ml collagenase/dispase in DMEM-S for 1 h at 37
• C. Microvascular capillaries were isolated by absorption on a column of glass beads (0.25-0.3 mm), after which the beads were washed with PBS. HBMECs were plated on rat tail collagen/fibronectin-coated dishes or glass coverslips, and cultured in RPMI 1640-based medium with growth factors, 10 % heat-inactivated FBS, 10 % NuSerum (BD Biosciences), heparin (5 units/ml), L-glutamine (2 mM), sodium pyruvate (1 mM), nonessential amino acids, vitamins, penicillin and streptomycin (100 units/ml). The viability of HBMECs was assessed by examining cellular morphology and by Trypan Blue exclusion. HBMECs were positive for Factor VIII-Rag. They took up fluorescently labelled acetylated LDL (low-density lipoprotein) and expressed γ -glutamyl transpeptidase, thus demonstrating their brain endothelial cell characteristics. HBMEC cultures were maintained in RPMI 1640-based medium, including 10 % FBS and 10 % NuSerum at 37
• C in a humid atmosphere of 5 % CO 2, as described previously [43] .
Association assay (or binding assay) of C. neoformans with HBMECs
Total HBMEC-bound yeast was determined as described previously [34, 40] with the following modifications. HBMECs were grown in collagen-coated 24-well tissue culture plates (Costar, Corning) until confluence. An inoculum of 10 6 Cryptococcus in 0.5 ml of experimental medium was added for 2 h at 37
• C for time-course studies or strain-dependent experiments. In the case of 10 6 cells per well, the m.o.i. (multiplicity of infection) is approximately 10. Free yeast cells were removed from HBMECs by washing with experimental medium four times. The adherent/invasive yeast cells were retained by the HBMECs. Subsequently, HBMECs were lysed with 0.5 % Triton X-100, diluted and plated on to blood or a YPD agar plate, and the colonies were counted. In the case of the time-course studies, the incubated cultures were harvested at indicated time points for colony counting. The viability of HBMECs was assessed by examining cellular morphology and by Trypan Blue exclusion. Results are presented as either the total colony number or the percentage binding of inoculum: [(number of Cryptococcus recovered)/(number of Cryptococcus inoculated)]×100 %.
Fluorescence microscopy
Samples for immunofluorescence microscopy were prepared as follows. HBMECs were plated on to glass coverslips (22 mm, square), which had been previously coated with type I collagen from rat tail (Upstate, 5-10 μg/cm 2 ) in an eight-well square culture system (Nalgen Nunc). HBMECs (∼5×10 4 cells) were seeded on to one coverslip 24 h prior to the experiment. HBMECs were prewashed four times with PBS, then fixed with 2 % (v:v) formaldehyde/PBS for 30 min at room temperature (25 • C). After an additional three washes with PBS, the HBMECs were blocked with 5 % non-fat dried skimmed milk/PBS for 30 min and then incubated with the T7-tag monoclonal antibody (Novagen, 1:500 dilution) at 4
• C overnight. The coverslips were then washed four times with PBS and propidium iodide (1 μg/ml) (Sigma) in 1 % BSA/PBS, and/or FITC-conjugated anti-mouse IgG (1:100 dilution) was added into each well for 1 h at 4
• C. Another three washes were applied before sealing the coverslips on to slides. Samples were examined under an immunofluorescence microscope at the Congressman Dixon Cellular Imaging Core Facility, Childrens Hospital Los Angeles. For cell-fusion studies, HBMECs were stained with 10 μM CellTracker Red dye or 10 μM CellTracker Green dye from a 10 mM stock in DMSO for 24 h respectively. The cells was washed with PBS once, trypsinized and combined into 4 ml of culture medium. Then 4 μg of gp41-I90 (approximately 0.25 μM) was added and incubated for 6 h. An aliquot of 150 μl of cell culture was added on to the slide with cytospin at 500 rev./min for 5 min. The cell spots were covered with 50 μl of fixing buffer. The resulting slide was examined using the fluorescence microscope. Under our experimental conditions (approximately 0.25 μM gp41-I90, 6 h co-culture), approximately one out of 5000 cells are completely fused, along with images of progressive fusion among the cells.
Electron microscopy
TEM
HBMECs were incubated with yeast cells for 3 h at 37
• C, washed four times with experimental medium, fixed with 4 % paraformaldehyde/2.5 % glutaraldehyde in PBS for at least 10 min at 4
• C, and carefully scraped from their support. The cell slurry was centrifuged for 10 min at 7000 g, and the HBMEC pellet was post-fixed with buffered 2 % osmium tetroxide for 1 h, dehydrated through graded ethanol solutions and propylene oxide, and embedded in Epon Ultrathin. Sections were then cut, stained with uranyl acetate and lead citrate, and examined with a Philips CM TEM.
SEM (scanning electron microscopy)
HBMECs grown on 24-well tissue culture inserts were incubated with C. neoformans strain B4500FO2 for 3 h. After yeast incubation, the endothelial cells were washed with a buffer containing 0.1 M sodium cacodylate and 0.2 M sucrose (SC buffer), fixed for 1 h in 2.5 % (v/v) glutaraldehyde in 0.1 M sodium cacodylate buffer at 25
• C, washed with SC buffer, postfixed with 1 % osmium tetroxide in SC buffer and dehydrated in an ethanol series. The endothelial cells in absolute ethanol were chemically dried using hexamethyldisalizane. The dried coverslips were attached to aluminum SEM stubs with doublesticky carbon tape, shadow-coated with gold/palladium vapour using a Pelco SC-7 Sputter Coater and scanned with an FEI XL30 environmental SEM. The ultrastructural methods have been reported previously [44] .
IEM (immunoelectron microscopy)
To identify ICAM-1, we applied a pre-embedding technique according to a method described previously [45] . Inserts were fixed for 3 h with 4 % formalin containing 0.25 % glutaraldehyde in a 0.1 M sodium cacodylate buffer at pH 7.3. The inserts were quenched with 0.1 M ammonium chloride to remove unbound aldehyde and then blocked with 10 % goat serum in PBS. The inserts were then immunoreacted with mouse antihuman ICAM-1 (1:100 dilution), goat anti-mouse biotinylated IgG (1:50 dilution), streptavidin-HRP (horseradish peroxidase) (1:50 dilution), and, finally, 3,3 -diaminobenzidine tetra-HCl. The inserts were post-fixed with 1-2 % osmium tetroxide and processed into plastic, as described in the TEM section above.
Preparation of membrane lipid rafts or microdomains from HBMECs
The Caveolae/Rafts Isolation kit was purchased from Sigma (catalogue number CS0750). For each sample, HBMECs were seeded and grown in a 60 mm Petri dish for 2 days. On the day of the experiment, the cells were individually incubated with either PBS buffer (control), or 0.25 μM of WT (wild-type) gp41-I90, mutant gp41-I90(D589L) or gp41-I90(T606A) individually for 3 h in the experimental medium with 1 % human serum. After incubation, the cells were washed with PBS three times, scraped in PBS and spun down at 750 g at 4 • C. Cell pellets were lysed in 200 μl of TN solution [25 mM Tris/HCl (pH 7.5), 1 mM DTT (dithiothreitol), a cocktail of protease inhibitors, 10 % sucrose and 1 % Triton X-100] on ice, and incubated for 30 min on ice. Samples were mixed with 1.16 ml of ice-cold OptiPrep TM , transferred into SW40 centrifuge tubes and overlaid with 2 ml each of 30 %, 30%, 25%, 20% and 0 % OptiPrep TM in TN buffer. The gradients were spun at 35 000 rev./min in an SW40 rotor for 5 h at 4
• C. Nine fractions (each of 0.5 ml) were collected from the top to the bottom of centrifuge tubes. For protein blots, 40 μl from each fraction was used. Anti-CD44 antibody (Santa Cruz Biotechnology, sc-7964, 1:300 dilution), anti-β-actin antibody (Santa Cruz Biotechnology, sc-8432, 1:400 dilution), anti-profilin antibody (Cell Signaling Technology, catalogue number 3237, 1:500 dilution) and an anti-rabbit-HRP conjugate (1:2000 dilution) were used in these experiments.
RESULTS
Effects of mutations in the HIV-1 gp41 core domain on C. neoformans binding to HBMECs
We have previously demonstrated that the synthetic gp41 ectodomain fragments gp41-I33 (amino acids 579-611) and gp41-I90 (amino acids 550-639) are able to enhance C. neoformans binding to HBMECs [35] . To determine the active site in the HIV-1 gp41, we designed gp41-I90, the major part of the gp41 core domain and several mutants with single point-to-point mutations in the NHR and CHR regions, including gp41-I90(D589L), gp41-I90(W596M), gp41-I90(T606A), gp41-I90(W610A), gp41-I90(W614A) and gp41-I90(W623A) ( Figure 1A ). These mutants have been previously identified as the defect in fusogenicity for targeting host cells [46] . The gp41-I90 and its mutants with His-tags were expressed in E. coli, affinity-purified and refolded in the FPLC Ni-NTA column. Presumably, they could automatically form hairpin core structure after purification and refolding ( Figure 1B) . SDS/PAGE indicated that each of them exhibited a single band with a molecular mass of approximately 12 kDa ( Figure 1C ). We then compared the enhancing effect of these purified His 6 -tagged polypeptides on C. neoformans binding to HBMECs. As expected, the WT gp41-I90 could significantly enhance C. neoformans binding to HBMECs ( Figure 1D , lane 2), in agreement with our previous finding [35] . Among the mutants, gp41-I90(D589L) and gp41-I90(W596M) had a similar or slightly lesser enhancing ability ( Figure 1D, lanes 3 and 4) , thus being considered as silent mutants. The gp41-I90(T606A) showed only background activity ( Figure 1D , lane 5), suggesting a loss-of-function mutant. The purified gp41-I90(W610A), gp41-I90(W614A) and gp41-I90(W623A) had approximately 50 % ability compared with the WT gp41-I90 ( Figure 1D, lanes 6-8) ICAM-1 is a membrane glycoprotein which is often up-regulated and/or translocated upon microbial pathogen infection [26] . In the present study we used IEM to investigate the potential effect of gp41-I90 on ICAM-1 expression on the surface of HBMECs, using C. neoformans for comparison. In the untreated control, the ICAM-1 signal was essentially undetectable (Figure 2A ). However, the purified gp41-I90 was able to up-regulate the ICAM-1 molecule as a scattered patch on the surface of HBMECs ( Figure 2B ). Similarly, once incubated with C. neoformans, the ICAM-1 signal could also be observed to a greater extent than that of the control on the surface of HBMECs ( Figure 2C ). Using an E. coli K12 strain as the control, no significant ICAM-1 signal was detected (results not shown). The results indicated that, like C. neoformans, the HIV-1 gp41 core domain is able to up-regulate ICAM-1 distribution on the surface of HBMECs. 
Induction of membrane ruffling on the surface of HBMECs by gp41-I90
Subsequently, we performed an immunofluorescence microscopic study to localize the gp41-I90-interaction sites on HBMECs. The gp41-I90 was fused with a T7 tag so that the mouse monoclonal antibody against the T7 tag and anti-mouse IgG-FITC conjugate (green) could be used to probe the gp41-I90. In parallel, propidium iodide (red) was used to stain host nuclear DNA. As shown in Figure 3 (A), little or no FITC staining was detected in the absence of gp41-I90. Only a slight background was observed on the smooth surface of HBMECs. The nucleus showed a bright red signal ( Figures 3B and 3C ). However, after pre-incubation with gp41-I90, HBMECs showed bright green signals as a folded or cluster structure on the surface membrane of HBMECs ( Figure 3D ). The nuclear structure seemed normal ( Figure 3E ). In an overlay image, gp41-I90 was shown to be localized on the surface membrane, rather than in the nucleus of the HBMECs, ( Figure 3F ) and its membrane localization was no longer as smooth as the control one, but appeared in clusters. This cluster localization can be envisaged more clearly on the enlarged images ( Figures 3G-3I) . Similarly, confocal microscopy images of these three sections of gp41-I90-treated HBMECs showed a significant membrane ruffling of the cell surface without overlapping with the nucleus (Figures 3J-3L ).
Figure 4 TEM and SEM images to show the morphological changes of HBMECs induced by the HIV-1 gp41-I90
HBMECs were grown on the collagen-coated plate until confluence for TEM studies. Untreated cells were used as the control (A). After incubating with gp41-I90 (20 μg/ml, or ∼1.32 μM) for 3 h, membrane ruffling could be observed near two HBMEC junctions (B, arrow), on the apical side of the HBMEC edge (C) or across the apical surface of HBMECs (D). For the SEM studies, HBMECs were grown until 50-70 % confluence was reached, so individual cells were distinct. The induced membrane ruffling can be observed on the lower margin of the cell (E, arrow 1). Significant membrane activities (E, arrows 2 and 3) can also be observed on the two ends of HBMECs in (E), and it may sometimes display across the entire HBMEC surface. A cluster of tubular structures (microvilli-like) was amplified, as shown in (F). Scale bar = 5 μm.
Morphological changes of HBMECs induced by gp41-I90
To further explore the effect of gp41-I90 on HBMECs at a higher resolution, we performed TEM and SEM studies to examine the membrane activity of HBMECs after gp41-I90 treatment. The untreated HBMECs showed little membrane activity ( Figure 4A ), whereas gp41-I90 could stimulate apical membrane ruffling (or lamellipodia-like structures) and the formation of microvilli (or filopodia) ( Figures 4B-4D ). The result is consistent with that from our immunofluorescence microscopic study, which showed that gp41-I90 induced a rough membrane contour on the surface of HBMECs after gp41-I90 treatment ( Figure 3D ). The nuclear morphology seemed normal, but vacuolization of the cytoplasm was evident ( Figure 4B ). The membrane activities induced by gp41-I90 had, in general, a tendency to reveal themselves on the edge of HBMECs, i.e. near the junction between cells ( Figure 4B , arrow). This was observed by viewing a section of an HBMEC showing much more membrane activity at its edge ( Figure 4C ). Either prolonged incubation or a higher concentration of gp41-I90 increased membrane activities across the HBMEC apical side ( Figure 4D ). Consistent with these findings, the SEM images showed that lamellipodia folded on the margin of the HBMEC membrane after gp41-I90 treatment ( Figure 4E , arrow 1). Clusters of tubular membrane structures were frequently observed ( Figure 4E , arrow 2 and 4F) or microvilli ( Figure 4E , arrow 3) existed at the end of HBMECs. A cross-section of these SEM membrane structures may reveal the TEM image of membrane activities, as shown in Figures 4(B)-4(D) . These membrane cluster structures may be the location of gp41-I90 signals as shown in the previous immunofluorescence images ( Figure 4D ). It is obvious that the HIV-1 gp41-I90, like C. neoformans [34] , is able to induce morphological changes of the HBMEC membrane, presumably the result of cytoskeletal rearrangement in HBMECs. Our result is also consistent with a report that HIV-1 virions are mingled with exuberant microvilli structures on the surface of the HBMECs during viral entry [33] .
Translocation of CD44 and β-actin to the membrane lipid rafts of HBMECs elicited by gp41-I90
C. neoformans can induce morphological changes of HBMECs during their engagement [34] . This morphological alteration includes the translocation of a subpopulation of CD44 molecules and β-actin molecules to the host membrane lipid rafts. In the present study we examined whether gp41-I90 could affect the HBMECs in a similar way. Its silent mutant gp41-I90(D589L) and its loss-of-function mutant gp41-I90(T606A) were tested in parallel.
HBMECs were first treated with the purified gp41-I90 or its mutants, and then lysed in a buffer containing 1 % Triton X-100. The fractionation was performed in OptiPrep TM densitygradient centrifugation. After centrifugation, detergent-insoluble membrane lipid raft fractions, as expected, floated to the interphase between 0 % and 20 % OptiPrep TM layers, peaking at fraction 2 in our study (asterisk in Figure 5 ). The loading buffer floated to the top (fraction 1), soluble proteins to the middle (fractions 3-6), and the cytoskeleton-associated detergentinsoluble proteins remained in the bottom fractions of the gradient (fractions 7-9). Protein blotting of each fraction was used to examine the distribution of protein components from HBMEC extracts of the gp41-treated samples.
Initially, we tested CD44 redistribution upon treatment with different gp41-I90 proteins. Both the WT gp41-I90 and silent mutant gp41-I90(D589L) induced CD44 redistribution to the membrane lipid raft (fraction 2). However, there was little effect by the loss-of-function mutant gp41-I90(T606A) ( Figure 5 , top panel). Since β-actin was also redistributed to the membrane lipid raft during C. neoformans engagement, we thus also compared the effect of gp41-I90 and its mutants on β-actin redistribution. Similarly, the effect of the WT gp41-I90 and gp41-I90(D589L) on β-actin redistribution was quite robust, whereas gp41-I90(T606) exhibited much less effect ( Figure 5, middle panel) . These results suggest that the critical site for the gp41 core domain to induce CD44 and β-actin redistribution to the membrane lipid raft is localized in the CHR region.
Profilin was also examined, as C. neoformans can enhance its protein level through the host PKCα (protein kinase Cα) activation pathway. As shown in Figure 5 , bottom panel, profilin was mainly detected in the cytoskeleton fractions, but showed more protein distributed in the treated samples of the WT gp41-I90 and the mutant gp41-I90(D589L). Slightly more soluble profilin signals (fractions 5 and 6) were observed in the gp41-I90-treated samples. Taken together, the HIV-1 gp41 core domain, similar to C. neoformans, could alter HBMEC membrane lipid raft structure.
Unlike C. neoformans, gp41-I90 did not induce PKCα phosphorylation in HBMECs
During C. neoformans infection, phosphorylation of PKCα was induced, and PKC enzymatic activity was detected in the HBMEC membrane fraction [47] . This activation is essential for the invasion of C. neoformans into HBMECs. In the present study we examined whether the HIV-1 gp41 core domain would have a similar effect on the PKCα phosphorylation in HBMECs. Using anti-phospho-PKCα-specific antibodies, we examined the phosphorylation of PKCα in HBMECs, which were treated with gp41-I90 and C. neoformans strains H99 and C1186. Protein blots were performed to examine their PKCα phosphorylation ( Figure 6, top panel) and the ECL (enhanced chemiluminescence)
Figure 5 Induction of reorganization of lipid rafts by gp41-I90 and its mutants
HBMECs were treated with either PBS (buffer), the purified gp41-I90 (WT), gp41-I90(D589L) or gp41-I90(T606A) for 2 h, as marked on the right-hand side. The cells were then lysed in buffer containing 1 % Triton X-100 on ice. Fractionation was performed in OptiPrep TM gradients, and nine fractions were collected. The lipid raft fractions are indicated by * in fraction 2. An equal volume of each sample was analysed by dot blots using antibodies against CD44, β-actin and profilin, as shown on the left-hand side. Redistribution of CD44 and β-actin on the membrane rafts was observed in WT HIV-1 gp41-treated HBMECs.
films (protein blots) were scanned by ImageMaster 2D Platinum 6.0 software for quantitative and graphical analyses ( Figure 6 , bottom panel). As shown, the treatment with purified gp41-I90 did not enhance PKCα phosphorylation (lanes 2 and 3) , whereas upon C. neoformans treatment, the phospho-PKCα significantly increased in HBMECs, as expected. Thus our results suggest that C. neoformans may have relayed a signal to the PKCα pathway in HBMECs, whereas HIV-1 gp41-I90 failed to do so.
Induction of syncytium formation in HBMECs by gp41-I90
In the process of studying the interaction between HIV-1 gp41-I90 and HBMECs, we were able to observe some large-sized HBMEC masses after incubation with HIV-1 gp41-I90 (Figure 7) . We used an immunofluorescence microscope to examine this phenomenon more closely. In these studies, HBMECs were stained with antibodies against CD44 (FITC conjugate, green), caveolin-1 (rhodamine-conjugate, red), and DAPI (4 ,6-diamidino-2-phenylindole, blue). Both green and red signals showed the HBMEC as a mass, whereas DAPI stain more obviously showed a multinucleate syncytial cell ( Figure 7A ). On the other hand, the gp41-I90(T606A) mutant protein could not induce detectable syncytium on HBMECs under the same experimental conditions ( Figure 7B ). With the purified gp41-I90, the induced syncytium was robust and could be easily observed within an incubation of 2 h, and the maximum number of syncytia was typically attained by 20 h after treatment (results not shown). Thus our results suggest that the gp41 core domain may play a major role in the induction of syncytium in HBMECs. Although it is well-known that gp41 can induce fusogenicity of many cell types [48] [49] [50] , the results of the present study show, for the first time, that the HIV-1 gp41 core domain is able to induce syncytium in HBMECs.
To confirm the biological relevance of this finding, we used the HIV-1 virus to perform the same experiments. In this study, HIV-1 with different m.o.i. (m.o.i. = 0, 0.1, 0.2 and 0.5, individually) were incubated with HBMECs for 24 h. The resulting cultures were washed and stained with anti-CD44 antibody (green) and DAPI (blue). In the control and low titre (m.o.i. = 0.1) samples, the syncytial cell was not evident ( Figure 7C, top panels) ; however, in the higher m.o.i. samples (m.o.i. = 0.2 or 0.5), many syncytia could be observed ( Figure 7C , bottom panels). They were large, flat and multinucleated. In general, the CD44 signal (green) was more evenly distributed. Taken together, the results of the present study are the first demonstration that (i) HBMECs can form syncytium and (ii) the core domain region of gp41 is the active domain for this syncytial activity.
We further performed a cell-fusion study to confirm the syncytium. Two distinct fluorescent cytoplasmic probes, CMTPX (red) and CMTDA (green), were used to verify the cytoplasmic exchanges between HBMECs. These reagents, once inside the cell, result in cytoplasmic staining. HBMECs were first stained with these two dyes for 24 h, separately ( Figure 8A , first two panels); then the co-culture was performed in the absence ( Figure 8A HBMECs were pretreated with (A) gp41-I90 compared with (B) mutant gp41-I90(T606A) for 3 h and then subjected to the following analyses. Immunofluorescence microscopic images were obtained using anti-CD44 (green) and anti-caveolin-1 (red) antibodies. DAPI was used to stain nuclear DNA. In the HBMECs treated with WT gp41-I90, a large mass of syncytial cell can be observed (arrow). In HBMECs treated with mutant gp41-I90(T606A) protein, no syncytium can be observed. (C) HBMECs were incubated with HIV-JRFL virions [56] at different m.o.i. as indicated for 24 h. HBMECs were then stained with CD44 (green) and DAPI (blue). A large bi-nucleate and tetra-nucleate syncytial cell was observed in m.o.i. = 0.2 and 0.5 samples (arrow) respectively. Scale bar = 25 μm. cells, the co-culture was diluted, plated on to the chamber slide and then examined using a confocal microscope. A fused cell was scanned from the top to the bottom with 1 μm in each section. In Figure 8 (B), a central section of a fused HBMEC is shown as split images. A binucleated cell can be observed by the DAPI stain (blue) ( Figure 8B, first panel) , whereas the green and red signals distributed throughout the cytosol ( Figure 8B , second and third panels respectively). The overlaid image is shown in the fourth panel of Figure 8 immune-compromised individuals and, most noticeably, in AIDS patients. As such, annually more than one million people succumb to this fungal pathogen. As cryptococcal meningitis is often associated with AIDS, our intention was to understand how gp41 enhances cryptococcal binding to HBMECs, the major component of the human BBB, which forms the interface between the blood and CNS to exclude most blood-borne substances, such as viruses, from entering the brain.
Using the recombinant polypeptides of the gp41 core domain, gp41-I90 and its mutants (Figure 1) , we found that the active site of the gp41 core domain for enhancing C. neoformans binding to HBMECs is located in the CHR region, rather than the loop region, since mutations of residues of Thr 606 , Trp 610 , Trp 614 and Trp 623 resulted in significant reduction of their enhancing activity ( Figure 1D ).
C. neoformans and gp41-I90 could also up-regulate ICAM-1 signals on the surface of HBMECs (Figure 2 ), suggesting that fungi and HIV-1 may share a similar mechanism by which they invade the CNS. We have previously demonstrated that apical membrane protrusions of HBMECs were induced during C. neoformans invasion [34] . Therefore we used both immunofluorescence (Figure 3 ) plus TEM and SEM (Figure 4) to examine whether the gp41 hairpin core structure could induce morphological changes in HBMECs. Indeed, our results revealed that gp41-I90 was able to induce considerable morphological changes in HBMECs (Figures 3 and 4) , in a manner similar to C. neoformans. We thus conclude that the gp41-I90 core domain may manipulate the cytoskeletal system of the host cells, including HBMECs, to facilitate the binding and/or invasion of microbes, like C. neoformans.
One interesting observation is that HIV-1 gp41-I90 can induce syncytium of HBMECs ( Figure 7A ). This is not an artefact due to the recombinant peptide, as HIV-1 virions can also induce syncytium on HBMECs. In our studies, we intended to use a low amount of virions to reduce potential biohazard. The multinucleated HBMECs can still be observed with m.o.i. at 0.5 with a 24 h incubation ( Figure 7C ). On the other hand, the yield of recombinant gp41-I90 is high (∼3 mg/l) and the same cellular effects can be safely induced on a short time incubation (2 h). We usually used approximately 0.25 μM gp41-I90 for our studies. This is equivalent to ∼3×10 13 gp41-I90 molecules in a chamber slide (0.2 ml with a 1 cm 2 surface area). Based on the average area of the viral envelope (0.152 μm 2 ), this area could be saturated with 5×10
14 vrial gp41 molecules. The amount of gp41-I90 we used was sufficient to induce syncytium within 2 h ( Figure 7A ). Interestingly, we found that gp41-I90 could also induce syncytium formation in human cell lines, including Jurkat (T-lymphocytes) and HEK-293T [HEK (human embryonic kidney)-293 cells expressing the large T-antigen of SV40 (simian virus 40)], but it did not induce syncytia in other human cell lines, such as HT080 (fibrosarcoma), N144 (fibroblast), Caco-2 (intestinal epithelium), RCH4W or BEL1 (both are B-lymphocytes) (results not shown). These results suggest that the gp41-I90-induced syncytium formation in human cells is cell-type specific. The reason for this cell specificity is currently unknown. Nevertheless, the results clearly reveal a unique function of the core domain of the HIV-1 gp41 molecule.
In all retroviruses, the two helices at the core domain are separated by a region of variable length containing a highly characteristic Cys-(X) 5-7 -Cys motif, in which the two cysteine residues are engaged in a disulfide link [51] . gp41-I90 (amino acids 550-639) covers the tip of the disulfide-bond region at the core domain of gp41 and extends to the two flanking ends. It may form the hairpin structure, which represents the stable and final conformation adopted by the core domain of gp41 during the fusion process. It is known that the mutations in the loop region of gp41 affect the formation and dilation of fusion pores. Such mutations also inhibit syncytium ability and HIV-1 entry [46, 48, 52, 53] . Our studies reveal additional roles of gp41-I90 on HBMECs, including ICAM-1 expression and membrane ruffling, which may be related to the infectivity of HIV-1 and C. neoformans to HBMECs. Indeed, the in vitro binding of C. neoformans to HBMECs is a unique functional assay for the gp41 molecule. That is, we speculate that both fungus and HIV-1 virus may elicit a similar signal, such as ICAM-1 expression (Figure 2 ) and membrane activation (Figures 3-5) , to facilitate their invasion. In this scenario, HIV-1 infection studied by others reveals the involvement of membrane rafts, intact actin and signalling in the viral invasion process. The CD4 receptor is able to transmit its signal through cytoskeleton association of p56 lck tyrosine kinase during HIV-1 infection in human Tcells [54] . Treatment of cytochalasin D [an inhibitor of F-actin (filamentous actin) polymerization] results in the loss of HIV-1 infection in peripheral blood mononuclear cells [55] . Whether the gp41 core domain plays any role in these activities on fungal invasion remains to be demonstrated. Nonetheless, like HIV-1 virus, the induced macropinocytosis process may engulf the yeast cells into the host cells, as an example of one simple mechanism [33] . However, one should keep in mind that the cell size of C. neoformans (∼5 μm in diameter plus capsule) is much larger than that of HIV-1 virus. Therefore we favour another speculation which suggests that the HIV-1 gp41 core domain may activate the membrane structure and induce cytoskeletal rearrangement. The gp41 core-induced cell signals may converge at that point, which is also induced by C. neoformans during its invasion. Thus we can observe the enhanced invasion both in vitro and in vivo [35] .
The invasion mechanisms of C. neoformans and HIV-1 may not always be the same, i.e. the HIV-1 gp41-I90 and virus can induce syncytium on HBMECs, but C. neoformans cannot (Figure 7) . Nevertheless, our results clearly demonstrate that the core domain of gp41 is a functionally active domain and that the significance of the induced syncytium by the gp41-I90 is at least 2-fold. First, it provides a useful model to study the post-fusion activity induced by gp41-I90. Secondly, the subsequent effect on the integrity of the BBB may be related to neuropathology of HIV-1 brain infection. Perturbation of the BBB may also facilitate C. neoformans brain infectivity.
In summary, HIV-1 is able to exacerbate C. neoformans invasion of the CNS by activating the membrane activities of brain endothelial cells via the gp41 core domain. This results in a deteriorating cryptococcosis in the infected host. The cispredilection factor (or cryptococcal neurotropic factor) of C. neoformans to the brain is currently unknown. However, the present study raises an interesting possibility that HIV-1 gp41 may play a role as a trans-predilection factor (or exogenous neurotropic factor) for C. neoformans CNS invasion. This present study provides important information for understanding how the HIV-1 gp41 core domain enhances cryptococcal invasion into the human brain, which may be helpful in the development of novel strategies to prevent cryptococcal meningitis in HIV/AIDS patients.
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